Michael Atkins, MD, Lombardi Comprehensive Cancer Center, Washington DC, shares treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab plus ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (Phase II HCRN GU16-260 (NCT03117309) Cohort A). Data were analyzed from 128 patients with clear-cell aRCC treated with first-line nivolumab monotherapy for up to 2 years. At 36 months from enrollment, 68.3% of patients were alive: 96.8% of IMDC patients who were favorable-risk and 56.6% of those with intermediate/poor-risk, respectively. The 36-mo mean TFS for the whole population was 9.4 months. For patients who were favorable risk the mean TFS was 12.9 months, of which TFS with grade 3+ treatment-related adverse events (TRAEs) was 1.5 months. For patients who were intermediate/poor risk, the mean TFS was 8.0 months, of which TFS with grade 3+ TRAEs was 1.0 months. At 36 months, 65.6% of patients who were favorable-risk and 27.1% of patients who were intermediate/poor-risk were alive and second-line treatment-free. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть